Oncology
Refine Search
Pharmaceutical
UK pharma major AstraZeneca today released positive high-level results from the CAPItello-281 Phase III trial showing that its Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT). 25 November 2024
Biotechnology
Research news last week included US biotech releasing early data for its FT819 in the treatment of systemic lupus erythematosus (SLE), which sent the firm’s shares leaping as much as 70%. Also, Netherlands-based NewAmsterdam Pharma announced positive data on its obicetrapib and ezetimibe combination in cardiovascular disease. On the regulatory front, Dutch firm argenX and China’s Zai Lab gained approval from the Chinese medicines regulator for their Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) care. Meantime, USA-based Kura Oncology signed a collaboration with Japan’s Kyowa Kirin on the development of ziftomenib for myeloid leukemia (ALS). 24 November 2024
Pharmaceutical
Japanese mid-size drugmaker Otsuka Pharmaceutical announced that it has entered into an exclusive worldwide licensing agreement with Ionis Pharmaceuticals for rights to manufacture and market Ionis' ulefnersen (ION363), a drug candidate under development for the treatment of patients with amyotrophic lateral sclerosis (ALS) caused by mutation of the fused in sarcoma (FUS) gene. 23 November 2024
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Japanese drugmaker Daiichi Sankyo (TYO: 4568) saw its shares rise more than 4% to 8.712 yen, after it revealed another multi-billion licensing deal, potentially worth $6 billion. 27 July 2020
Biotechnology
The US Food and Drug Administration has granted accelerated approval to Tecartus (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 27 July 2020
Pharmaceutical
At its July meetings this week, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended nine novel medicines for approval, including a medicine for use in countries outside the European Union and one biosimilar. 25 July 2020
Biotechnology
North Carolina, USA-based oncology specialist G1 Therapeutics has signed a license agreement for lerociclib to EQRx, a biopharmaceutical company focused on making innovative medicines at dramatically lower prices for the benefit of people and society. 24 July 2020
Biotechnology
Dutch biotech firm Synaffix today announced that Swiss oncology-focused drug discovery firm ADC Therapeutics has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies. 23 July 2020
Biotechnology
Shares of Swiss pharma giant Roche were down more than 2% in early trading today, after it revealed that second-quarter 2020 sales fell 9.6% to 14.1 billion Swiss francs ($15.20 billion). Factoring out the strength of the franc, revenue dropped 4%. 23 July 2020
Biotechnology
Japanese drugmaker Daiichi Sankyo has teamed up with Paris-based cancer research institute Gustave Roussy in a multi-year, multi-study research collaboration. 22 July 2020
Biotechnology
Houston, USA-based CNS Pharmaceuticals has lined up both American and European manufacturers for berubicin, its lead drug candidate for the treatment of glioma brain tumors. 21 July 2020
Pharmaceutical
Swiss pharma giant Novartis was trading 1.5% lower on Tuesday lunchtime after presenting its financial results for the second quarter of 2020. 21 July 2020
Pharmaceutical
Spanish drugmaker PharmaMar has submitted lurbinectedin (trade name Zepzelca) for “Temporary Authorization” for marketing to the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with small cell lung cancer (SCLC) who have progressed after prior platinum-containing therapy. 20 July 2020
Biotechnology
China’s Antengene Corporation has successfully closed a $97 million Series C financing. 20 July 2020
Pharmaceutical
Last week’s notable research news included disappointing results for Swiss pharma giant Roche’s Tecentriq in combination with Avastin in the treatment of ovarian cancer, and US firm Moderna posted promising results for its COVID-19 vaccine candidate mRNA-1273, but questions were raised about the length of protection it provided. Roche was also in the news for its collaboration with Blueprint Medicines on the development of the US biotech’s targeted cancer candidate pralsetinib. Elsewhere, India’s Biocon received approval from the domestic regulator, the DCGI, to market its Alzumab to treat respiratory complications in COVID-19 patients. 19 July 2020
Biotechnology
Nerlynx, (neratinib), a new breast cancer drug shown to significantly reduce the risk of cancer recurrence, is now approved for use in Malaysia. 17 July 2020
Pharmaceutical
The UK subsidiary of Japan’s Astellas Pharma revealed yesterday that National Institute for Health and Care Excellence (NICE) has recommended Xospata (gilteritinib) in its Final Appraisal Document (FAD) for adult patients with relapsed or refractory (resistant to existing treatment) FLT3 mutation-positive acute myeloid leukemia (AML). 17 July 2020
Pharmaceutical
US giant Johnson & Johnson on Thursday became one of the first healthcare giants to show what damage has been done to its sales and profits by the COVID-19 pandemic. 16 July 2020
Biotechnology
Guangzhou, China-based LintonPharm is launching a Phase III trial program for catumaxomab in peritoneal carcinomatosis, a form of advanced gastric cancer. 16 July 2020
Biotechnology
A US Food and Drug Administration (FDA) advisory committee has voted in favor of the demonstrated benefit of treatment with belantamab mafodotin outweighing the risks for relapsed or refractory multiple myeloma patients, who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. 15 July 2020
Biotechnology
US tumor drug resistance specialist Deciphera Pharmaceuticals today announced that the Australian Therapeutics Goods Administration (TGA) has approved Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. 14 July 2020
Biotechnology
US precision cancer therapy specialist Blueprint Medicines has entered into a global collaboration with Swiss giant Roche and its subsidiary Genentech, worth a potential $1.7 billion. 14 July 2020
Biotechnology
US pharma giant Pfizer has announced the registration of Bisponsa (inotuzumab ozogamycin), which is an innovative drug, designed for the treatment of acute lymphoblastic leukemia (ALL), in Russia. 14 July 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze